Because little is known about the pathogenic mechanisms underlying these disorders, no effective strategy has been developed to prevent their occurrence (4,5).
Others suggest that viral virulence may play a role in the pathogenesis of DHF/DSS (11,12).
However, although many theories have been put forward, the main mechanism underlying the development of DHF/DSS remains unknown.
Several viruses have similar antigenic determinants that make them able to mimic host proteins (13,14), a phenomenon known as molecular mimicry. These viruses often initiate the generation of autoantibodies against the host's own tissues (15) (16) (17) . The presence of cross-reactive antibodies against endothelium after infection by human cytomegalovirus (hCMV), Ebstein-Barr virus (EBV), and human immunodeficiency virus (HIV) is well-documented (17) (18) (19) . The association of the autoantibody induced by hCMV infections and systemic sclerosis is a good example. The serum antibodies that induce endothelium apoptosis in patients of systemic sclerosis also recognize the late protein UL94 of hCMV (17) . The clinical onset of systemic sclerosis is associated with the generation of pathogenetic autoantibodies by chronic infection of hCMV (20, 21 (23, 24) . Once the binding occurs, endothelial cells undergo nitric oxide-mediated apoptosis (23) , an effect that can be blocked by recombinant NS1 protein (24) .
Together, these findings suggest that the endothelial dysfunction caused by the induction of autoantibodies through host-virus interplay may be one of the factors in the pathogenesis of DHF/DSS. Understanding the molecular target of DV autoantibodies may, therefore, be important for diagnosis and the design of a suitable safe vaccine against this viral disease.
In this study, we generated many anti-DV mAbs and successfully identified an anti-DV NS1 mAb, DB16-1, which was found to cross-react with HUVECs and human blood vessels. The protein targeted by DB16-1 was isolated by immunoprecipitation, and designated Lysine-Rich CEACAM1 co-isolated (LYRIC), a finding further confirmed by mass spectrometry.
LYRIC protein is also called metadherin (25) , 3D3 (26) or astrocyte elevated gene-1 (AEG-1) (27) and is highly conserved between species Immnofluorescence-HUVECs were grown on cover slips then rinsed with PBS and fixed with 2% paraformaldehyde followed by incubation with mouse anti-NS1 hyper-immune sera (1:500 dilution), DB16-1 (10 μg/ml), 4G2
(10 μg/ml) antibodies and normal mouse sera (NMS) (1:500 dilution) or normal mouse IgG (NMIgG) (10 μg/ml) for 1 hr at RT. antibodies following the same procedures described above in "Western blotting."
Statistical analysis-Statistical results were tested using the unpaired Student's t tests as appropriate. P< 0.05 was considered significant. (Fig. 1D) . We further investigated whether DB16-1 could bind to human blood vessels by double immunostaining. We found that DB16-1 could bind to the blood vessels in surgical specimens of human lung tissues through immunofluorescent localization (Fig.   1E, b) . The target protein of DB16-1 was found to be co-localized with an endothelial marker ulex europeus agglutinin-I (UEA-I) in the blood vessels of human lung tissues (Fig. 1E, c) . The nuclear staining was performed by Hoechst 33258 (Fig. 1E, d ).
RESULTS

Serum
Because DB16-1 could bind to HUVECs in immunofluorescence staining (Fig. 1D) to HUVECs (Fig. 2A) . Notably, all of HUVECs were recognized by the endothelial marker CD31, but only some of them (39%) were recognized by DB16-1 ( Fig. 2A) HUVECs apoptosis by TUNEL assay (Fig. 2C ).
Complement-dependent cytotoxicity assay also demonstrated more HUVECs (45%) underwent lysis after binding to DB16-1 than binding to 4G2 did (31%) (Fig. 2D ). These two experiments confirm that endothelial damage (18%) (Fig. 3E ). These data highly suggest that both NS1 of dengue viruses and human LYRIC protein are the targets of DB16-1. (Fig. 4A, right (Table 1) . It was interesting to note that this consensus motif matched the amino acid residues 116 to 119 in NS1 of four dengue virus subtypes (Table 1) . To confirm the specificity of the selected phage clones, ELISA plates coated with DB16-1 were incubated with control phage HB47-1 and phage clone PC16-10, the most homologous to DV NS1. We found that PC16-10 bound specifically to DB16-1 in a dose-dependent manner, but control phage did not (Fig. 5B) . A synthetic peptide, SP16-1 (LRYSWKTWGKAK), corresponding to amino acid residues from 111 to 122 of D2NS1, was recognized by DB16-1 in a dose-dependent manner. In contrast, control peptide SP5-52 was not recognized by DB16-1 (Fig. 5C ). Control antibody NMIgG did not bind to SP16-1 and SP5-52 (Fig. 5D) . Furthermore, peptide competition assay indicated that binding activity of DB16-1 to D2NS1 protein was competitively inhibited by SP16-1 in a dose-dependent manner, but an arbitrary control peptide P7M was incapable of inhibiting the binding activity of DB16-1 (Fig. 5E ). These results suggested that DB16-1 recognized the epitope corresponding to amino acid residues 111 to 122 of NS1 of dengue viruses. anti-LYRIC antibodies: Lyric 1-7, Lyric 2-1, Lyric 3-13, and Lyric 4-7 (Fig. 4A ). These findings confirmed that DB16-1 was cross-reactive with human LYRIC. Previously, LYRIC has been reported to be a highly conserved protein among species (26) , and has been found to be associated with the progression and metastasis of diverse cancers (25, 27, 38) , though its cellular function remains unknown.
DB16-1 and anti-LYRIC antibodies recognize LYRIC protein and HUVECs-To
NS1 protein of dengue viruses and LYRIC protein contain the same binding motif for
DB16-1-When
It is important to define the B-cell epitope of DB16-1 to identify the cross-reactive epitope in the host antigen (17, (39) (40) (41) . Using phage display, we identified a consensus motif of DB16-1,
K-x-W-G, located in amino acid residues 116 to 119 in all four subtypes of DV NS1 proteins (Table 1 ). The selected phage PC16-10, not the control phage, bound to DB16-1 in a dose-dependent manner, indicating that PC16-10 interacted with DB16-1 through its displayed peptide rather than another part of phage particle (Fig. 5B) . The synthetic peptide SP16-1 inhibited DB16-1 binding to D2NS1 (Fig. 5E ), indicating that amino acid residues 111 to 122 of the DV NS1 protein made up the B-cell epitope of DB16-1.
To investigate the molecular mimicry of DV NS1 and LYRIC, we compared the amino acid sequences of these two proteins. Interestingly, both proteins contained a K-x-W-G motif ( Fig.   6A ) and this consensus motif was recognized by autoantibody DB16-1 by phage display method (Table 1 , Fig. 5 ). Synthetic peptide SP-Ly, which corresponded to amino acid residues 330-339 of human LYRIC (Fig. 6A) , was recognized by DB16-1 in a concentration-dependent manner (Fig. 6B) .
Furthermore, the ability of DB16-1 to bind to SP-Ly peptide could be competitively inhibited by SP16-1 peptide (Fig. 6C) . Complement-dependent cytotoxicity assay was performed by flow cytometry in LYRIC-expressed HEK293T cells treated with complement alone, DB16-1 (50 μg/ml) with complement, isotype mAb (50 μg/ml) with complement with and 4G2 (50 μg/ml) with complement. clones PC16-10 and HB47-1. These two phages were serially diluted from 10 9 to 10 4 pfu, and 0 pfu.
The PC16-10 bound to DB16-1 specifically, but control phage HB47-1 did not. C and D. Synthetic peptide corresponding to D2NS1 protein (SP16-1) bound with DB16-1 in dose-dependent manner.
NMIgG served as the negative control. E. Competitive inhibition of DB16-1 binding to D2NS1 by SP16-1 was confirmed by Western blotting. Control peptide P7M had no such effect. Figure 1 at LIFE SCIENCE LIBRARY, ACADEMIA SINICA, on January 13, 2011
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